An Introduction to Bladder Cancer
Bladder cancer is the most common malignancy involving the urinary system. While cisplatin-based chemotherapy and Bacillus Calmette-Guérin (BCG) remains the standard of care for muscle-invasive and non-muscle-invasive disease, respectively, the development of immune checkpoint inhibitors has transformed the management of advanced urothelial cancer, with atezolizumab, durvalumab and avelumab being approved for use following platinum-based chemotherapy or in as first-line treatment in platinum-ineligible patients. However, many patients fail to respond to these agents, and predictive biomarkers remain an unmet need. Emerging treatment options include combined immunotherapy approaches, targeted therapies and antibody-drug conjugates.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Bladder Cancer Content
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
An oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies.
- Identify adverse events promptly in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
- Use appropriate management strategies for the adverse events that arise in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
- Apply a multidisciplinary approach to the identification and management of adverse events in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
The Evolving Therapeutic Landscape and Role of Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Systematic Review
touchREVIEWS in Oncology & Haematology. 2023;19(1):27-34 DOI: https://doi.org/10.17925/OHR.2023.19.1.27
Bladder cancer is one of the most common malignancies in the USA, with an estimated 81,180 new cases and 17,100 deaths in 2022.1 Advanced urothelial carcinoma (aUC) includes both locally advanced, unresectable and metastatic urothelial cancer. About 5% of all bladder cancer cases present as de novo aUC, while almost 25% of patients present with muscle-invasive bladder cancer (MIBC). About 50% of these patients progress to aUC even with intent-to-cure locoregional therapy, […]
Frontiers in Non-metastatic, Muscle-invasive Bladder Cancer
touchREVIEWS in Oncology & Haematology. 2022;18(2):113–9
Bladder cancer (BC) is the sixth most common cancer in the world, accounting for 81,180 estimated new cases and 17,100 deaths in 2022.1 BC is most frequently diagnosed among people aged 65–74 years.1 For patients with disease limited to the bladder, the depth of invasion of the primary tumour is the most important prognostic variable in […]
The role of fibroblast growth factor receptor (FGFR) alterations in advanced urothelial carcinoma
Watch to learn more about FGFR alterations and how a consensus on molecular classification impacts our understanding of muscle-invasive bladder cancer.1,2
Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022
Watch this two-part activity exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer. Filmed following the ESMO 2022 Congress. Part 1: Watch urological cancer expert Prof. Axel Merseburger review key data from the ESMO Congress 2022 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
- Recall the latest efficacy data for new and emerging targeted treatments for patients with bladder cancer
- Describe the safety profile of new and emerging targeted treatments for patients with bladder cancer
- Discuss how the latest data on targeted treatments may affect the current and future management of patients with bladder cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Robert Jones, ASCO 2022: Maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma – Phase 2 ATLANTIS trial
Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma. Questions: What is the rationale for the use of cabozantinib in the […]
Neal Shore, AACR 2022: KEYNOTE-992 a Phase 3 Study of Pembrolizumab in Muscle-invasive Bladder Cancer
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
The evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
Dr Cora Sternberg considers the use of antibody–drug conjugates in urothelial carcinoma, including clinical trial data and adverse event management.
- Describe the rationale for and current role of antibody–drug conjugates in the treatment of urothelial carcinoma
- Discuss efficacy data for current and emerging antibody–drug conjugates in the treatment of urothelial carcinoma
- Explain the safety profile of antibody–drug conjugates in patients with urothelial carcinoma and approaches to managing possible adverse events
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!